These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20565970)

  • 1. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
    Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
    BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
    Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
    Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
    Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
    Lien EA; Søiland H; Lundgren S; Aas T; Steen VM; Mellgren G; Gjerde J
    Breast Cancer Res Treat; 2013 Sep; 141(2):243-8. PubMed ID: 23996142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
    Thota K; Prasad K; Basaveswara Rao MV
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
    Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
    Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
    Mürdter TE; Schroth W; Bacchus-Gerybadze L; Winter S; Heinkele G; Simon W; Fasching PA; Fehm T; ; Eichelbaum M; Schwab M; Brauch H
    Clin Pharmacol Ther; 2011 May; 89(5):708-17. PubMed ID: 21451508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
    Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
    Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Hauptmann M; van Schaik RH; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res Treat; 2013 Jun; 139(3):649-55. PubMed ID: 23736997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
    Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
    Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
    van Schaik RH; Kok M; Sweep FC; van Vliet M; van Fessem M; Meijer-van Gelder ME; Seynaeve C; Lindemans J; Wesseling J; Van 't Veer LJ; Span PN; van Laarhoven H; Sleijfer S; Foekens JA; Linn SC; Berns EM
    Pharmacogenomics; 2011 Aug; 12(8):1137-46. PubMed ID: 21830868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
    Lim JS; Sutiman N; Muerdter TE; Singh O; Cheung YB; Ng RC; Yap YS; Wong NS; Ang PC; Dent R; Schroth W; Schwab M; Chowbay B
    Br J Clin Pharmacol; 2016 Jun; 81(6):1142-52. PubMed ID: 26799162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.